[1] |
HU Xiaoyu, CAI Yuwen, YE Fugui, SHAO Zhimin, HU Weigang, YU Keda.
Impact of BRCA1/2 germline mutation on the incidence of second primary cancer following postoperative radiotherapy in patients with triple-negative breast cancer
[J]. China Oncology, 2024, 34(2): 185-190.
|
[2] |
LIU Zhiyu, XU Dong, CHEN Xihao, LI Jipeng.
Influencing factors and establishment of a prediction model for the tumor regression after neoadjuvant chemoradiotherapy in locally advanced rectal cancer
[J]. China Oncology, 2024, 34(2): 191-200.
|
[3] |
CHEN Hongyu, SU Pengyu, LUO Wenzi, PANG Dequan, WANG Feiran.
A study of relationship between cardiac exposure dose-volume and cardiovascular autonomic dysfunction in radiotherapy
[J]. China Oncology, 2024, 34(11): 1036-1044.
|
[4] |
CUI Jianchun, LU Wei, LI Qianyong.
Clinical application value of surface-guided automatic positioning in pelvic tumor radiotherapy
[J]. China Oncology, 2024, 34(10): 966-971.
|
[5] |
WANG Yan, SU Yue, HU Tu, LIU Qiying, YAO Weiqiang, CHEN Yong, YAN Wangjun, ZHANG Zhen.
Retrospective analysis of short-term efficacy and safety of preoperative radiotherapy for 33 cases of locally high-risk soft tissue sarcoma
[J]. China Oncology, 2023, 33(7): 693-700.
|
[6] |
BI Zhao, WANG Yongsheng.
New concept of de-escalation management strategy in breast cancer patients with 1-2 positive sentinel lymph nodes
[J]. China Oncology, 2023, 33(6): 560-565.
|
[7] |
DONG Xiaohuan, LIU Jun, LI Hongxuan, CHENG Yan, LI Yue, YU Wen, CAI Xuwei, FU Xiaolong.
Preliminary study on involving field irradiation radiotherapy in neoadjuvant chemoradiotherapy for esophageal cancer
[J]. China Oncology, 2023, 33(3): 267-273.
|
[8] |
TANG Tianci, ZHAI Zhoushijia, LI Shengwei, WANG Xiaoshen, NI Xiaochen.
Application of generalized equivalent uniform dose optimization in the treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy
[J]. China Oncology, 2023, 33(3): 274-281.
|
[9] |
WANG Yu, BI Nan.
Advancements in the research of immunomodulatory effects of radiation therapy: from basic to clinical
[J]. China Oncology, 2023, 33(12): 1083-1091.
|
[10] |
ZHUANG Han, LING Chifang, WANG Jiazhou, HAN Xu, JIANG Rui, HU Weigang.
Radiation therapy in locally advanced pancreatic cancer with 75 Gy simultaneous integrated boost: a dosimetric feasibility study
[J]. China Oncology, 2023, 33(1): 54-60.
|
[11] |
CAI Gang, WANG Shubei, CHEN Jiayi.
The current data and challenge of radiotherapy in the case management of gastric cancer
[J]. China Oncology, 2022, 32(7): 581-587.
|
[12] |
YU Silai, NI Jianjiao, ZHU Zhengfei.
Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects
[J]. China Oncology, 2022, 32(6): 487-498.
|
[13] |
ZHANG Qian, FANG Xiaoyan, LIU Juan, LIU Jin, CHENG Leilei, SUN Jing.
Study on the safety of simultaneous integrated boost and the importance of cardiac substructural dose assessment of hypofractionated radiotherapy after early left breast cancer breast-conserving surgery
[J]. China Oncology, 2022, 32(5): 427-435.
|
[14] |
WANG Jun, HE Ping.
Prognostic value of perineural invasion in ypⅠ-Ⅱ rectal cancer patients who received neoadjuvant radiotherapy
[J]. China Oncology, 2022, 32(12): 1229-1234.
|
[15] |
XU Xiaofei, ZHANG Lixia, DAI Heyang, CHEN Lingyun, XUE Jiaojiao, LI Qingxia.
Value of global longitudinal strain in assessing radiation-induced heart disease in breast cancer: systematic review and meta-analysis
[J]. China Oncology, 2022, 32(10): 971-978.
|